Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

924766e5-2820-455f-adb9-6c50c4f306a1 - samples

ABSTRACT: Whole-genome sequencing of frozen tumor biopsies from patients with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. 12 samples. Illumina HiSeq X-Ten.

PROVIDER: EGAD00001006086 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

ec0fecce-f82b-483c-a379-c0bc42418721 - samples

Project description:RNA sequencing of frozen tumor biopsies from patients with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. 6 samples. Illumina HiSeq 4000.

| EGAD00001006085 | EGA

4e0697e2-29b4-4772-bbc8-6c8a11941e3f - samples

Project description:Whole-genome sequencing (10X Genomics) of frozen tumor biopsies from patients with primary cutaneous anaplastic large cell lymphoma. 12 samples. Illumina HiSeq X-Ten.

| EGAD00001006176 | EGA

Whole-genome and transcriptome sequencing of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma

Project description:Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (pcAECyTCL) is a rare variant of cutaneous T-cell lymphoma with an aggressive clinical course and a very poor prognosis. We subjected tumor biopsies from patients with pcAECyTCL to whole-genome sequencing and RNA-sequencing to investigate genomic alterations and deregulated gene expression in the disease.

| EGAS00001004332 | EGA

dfd7837f-ddc6-4941-8c2a-285dc2393e70 - samples

Project description:RNA sequencing of frozen tumor biopsies from patients with primary cutaneous anaplastic large cell lymphoma. 12 samples. Illumina HiSeq 4000.

| EGAD00001006178 | EGA

MicroRNA profiling of primary cutaneous large B-cell lymphomas

Project description:High-throughput sequencing of primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) and in vitro activated peripheral blood B-cells. We performed high-throughput sequencing analysis on frozen tumor biopsies from 19 cases of PCFCL and PCLBCL-LT to establish microRNA profiles. Cluster analysis of the complete microRNome could not distinguish between the two subtypes, but 16 single microRNAs were found to be differentially expressed.

2013-10-18 | GSE51359 | GEO

MicroRNA profiling of primary cutaneous large B-cell lymphomas

2013-10-18 | E-GEOD-51359 | biostudies-arrayexpress

A new molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies

Project description:Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm displaying heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker, the "proliferation signature", using gene expression in fresh frozen material. Here we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies.

2017-03-17 | GSE93291 | GEO

Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma

Project description:T-cell landscape differences between cutaneous squamous cell carcinoma (cSCC) tumors in immune competent (SCC in IC) and immunocompromised organ transplant recipients (TSCC in OTR) are unclear. We developed an analytical method to define tumor infiltrating lymphocyte (TIL) phenotype in cSCC from immune competent and immune suppressed patients using single-cell TCR sequencing and gene expression data. TSCC exhibits reduced proportions of cytotoxic and naïve TILs and similar numbers of regulatory TILs. Fewer, more heterogeneous TCR clonotypes are observed in TIL from OTR. Most TCR sequences for top ten clonotypes correspond to known antigens, while 24% correspond to putative neoantigens. OTR show increased cSCC events over 12 months possibly due to reduced cytotoxic T-cells. Our novel method of barcoding CD8+ T-cells is the first providing gene expression and TCR sequences in cSCC. Knowledge regarding putative antigens recognized by TCRs with phenotypic function of T-cells bearing those TCRs could facilitate personalized cSCC treatments.

2020-06-03 | GSE145328 | GEO

fdd879d5-ebab-47a5-8487-c79dbe03721a - samples

Project description:Whole-exome sequencing of matched frozen tumor biopsies/granulocytes from patients with primary cutaneous anaplastic large cell lymphoma. 7 paired tumor/germline samples. BGISEQ-500.

| EGAD00001006177 | EGA

High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model

Project description:Major efforts are underway to identify agents that can potentiate effects of immune checkpoint inhibition. Here, we show that ascorbic acid (AA) treatment caused genome wide demethylation and enhanced expression of endogenous retroviral elements in lymphoma cells. AA also increased 5-hydroxymethylcytosine (5hmC) levels of CD8+ T cells and enhanced their cytotoxic activity in a lymphoma co-culture system. High-dose AA treatment synergized with anti-PD1 therapy in a syngeneic lymphoma mouse model, resulting in marked inhibition of tumor growth compared with either agent alone. Analysis of the intra-tumoral epigenome revealed increased 5hmC with AA treatment, consistent with in vitro findings. Analysis of the tumor immune microenvironment revealed that AA strikingly increased intra-tumoral infiltration of CD8+ T cells and macrophages, suggesting enhanced tumor immune recognition. The combination treatment markedly enhanced intra-tumoral infiltration of macrophages and CD8+ T lymphocytes, granzyme B production by cytotoxic cells (cytotoxic T cells and Natural Killer cells), and IL-12 production by antigen presenting cells compared with single agent anti-PD1. These data indicate that AA potentiates anti-PD1 checkpoint inhibition through synergistic mechanisms. The study provides compelling rationale for testing combinations of AA and anti-PD1 agents in lymphoma patients as well as in pre-clinical models of other malignancies.

2020-01-27 | GSE141444 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data